Back to Search
Start Over
Challenges in Clinical Trial Design for T Cell‐Based Cancer Immunotherapy.
- Source :
- Clinical Pharmacology & Therapeutics; Jan2020, Vol. 107 Issue 1, p47-49, 3p
- Publication Year :
- 2020
-
Abstract
- B Chimeric antigen receptor T cells can induce impressive response rates in patients with refractory B cell malignancies. Adoptive transfer of tumor infiltrating lymphocytes or T cell receptor-engineered T cells are other promising treatment modalities currently in clinical development. Requirements for clinical trial design for T cell-based cancer immunotherapy significantly differ from established criteria for small-molecule or antibody-based anticancer drugs. The development of cellular cancer immunotherapies is spurred by the success of anti-CD19 chimeric antigen receptor (CAR) T cells in B cell malignancies. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 00099236
- Volume :
- 107
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Clinical Pharmacology & Therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 140845042
- Full Text :
- https://doi.org/10.1002/cpt.1659